WO1999024042A2 - Stable antiandrogenic gel composition - Google Patents
Stable antiandrogenic gel composition Download PDFInfo
- Publication number
- WO1999024042A2 WO1999024042A2 PCT/US1998/023226 US9823226W WO9924042A2 WO 1999024042 A2 WO1999024042 A2 WO 1999024042A2 US 9823226 W US9823226 W US 9823226W WO 9924042 A2 WO9924042 A2 WO 9924042A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- amount
- androgen
- water
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
Definitions
- This invention relates to stable pharmaceutical compositions in the form of a gel which are suitable for treating acne and other androgen-related conditions, including seborrhea, hirsutism, and androgenic alopecia, in humans and which contain an antiandrogen compound dissolved or suspended in an alcohol-water solvent system and having an apparent pH value of no more than about 5 and a gelling agent
- n is an integer of 2 to 3
- pharmaceutical compositions containing such antiandrogens and methods of using such antiandrogens to treat androgen-dependent diseases including acne are included in the compositions containing such antiandrogens and methods of using such antiandrogens to treat androgen-dependent diseases including acne.
- the compounds of formula I are more stable to decomposition in an alcohol-water solvent system containing less than about 5 percent by weight water than in one containing pure alcohol or an alcohol-water solvent system containing more than about 5 percent by weight water, e.g., 6.2 percent by weight water; and (2) that the presence of a glycol such as propylene glycol in an alcohol solvent system accelerates degradation of the compounds of formula I; and (3) that an apparent pH of the alcohol-water solvent system of no more than about 5, preferably in the range ofmore than about 3 to less than about 5.0 enhances the stability of the compounds of formula I.
- This invention provides a pharmaceutical composition for topical treatment of androgen-related disorders which comprises (a) an amount of a compound represented by formula I effective to topically treat the androgen-related disorders
- n is an integer of 2 to 3; (b) an alcohol-water solvent system containing no more than about 5.0 weight percent water; and (c) a gelling agent in an amount sufficient to maintain the pharmaceutical composition in the form of a gel; and wherein the pharmaceutical composition has an apparent pH of less than or equal to about 5.
- This invention further provides a pharmaceutical composition for topical treatment of androgen-related disorders which comprises:
- n is an integer of 2 to 3;
- a buffer system capable of maintaining an apparent pH of the pharmaceutical composition at a value in the range of more than about 3 and less than about 5;
- This invention further provides a pharmaceutical composition for topical treatment of androgen-related disorders which comprises (a) an amount of the compound represented by formula II effective to topically treat the androgen- related disorders
- an ethanol-water solvent system containing more than about 1.0 to about 4.0 percent by weight water;
- a buffer system capable of maintaining an apparent pH of the pharmaceutical composition in the range of about 3.5 to about 4.5 and (d) an amount of a gelling agent sufficient to maintain the pharmaceutical composition in the form of a gel.
- an antiandrogenic gel composition comprising an amount of the compound represented by formula II effective to topically treat androgen-related conditions
- the compound of formula II was stable to decomposition in an alcohol-water solvent system containing no more than about 5.0 weight percent water, preferably about 1.0 to about 4.0 weight percent of water, and more preferably about 2.0 to about 3.0 weight percent of water
- the alcohols found useful in the present invention include water soluble alcohols including C2 to Cs straight and branched chain alcohols. Use of ethanol or 2-propanol is preferred; use of ethanol is more preferred.
- androgen-related conditions in humans are meant those androgen-related conditions including acne, seborrhea, hirsutism, and androgenic alopecia,
- the buffer systems found useful in the present invention are those buffer systems which are water soluble buffer systems, especially those soluble in the alcohol-water solvent system useful in the present invention and capable of maintaining an apparent pH of the alcohol-water solvent system of no more than about 5, preferably in the range of more than about 3 to less than about 5, more preferably a pH in the range of about 3.5 to about 4.5, and most preferably at a pH of about 4.
- suitable buffer systems include phosphoric acid/sodium phosphate monobasic; citric acid-sodium citrate and acetic acid/sodium acetate. Use of phosphoric acid/sodium phosphate monobasic is preferred.
- Other buffer systems capable of maintaining an apparent pH of about 3.5 to 4.5 in an alcohol- water system containing less than 10 weight percent water may also be used.
- the gelling agents found useful in the present invention are those which can maintain the pharmaceutical composition of the present invention in the form of a gel.
- suitable gelling agents include alkyl- and hydroxyalkyl ethers of cellulose including hydroxyethylcellulose, hydroxypropylcellulose, methylcellulose derivatives as well as carboxypolymethylene (which is highly ionic and slightly acidic) such as those carboxyvinylpolymers sold under the tradenames carbomers and carbopol.
- carboxypolymethylene which is highly ionic and slightly acidic
- Use of hydroxypropylcellulose is preferred.
- the amount of gelling agent found effective to maintain the pharmaceutical compositions of this invention in the form of a gel is at least about 2 weight percent of the composition, preferably in the range of about 2 to about 5 weight percent , and more preferably about 2 to about 3 weight percent , and most preferably about 2.5 weight percent of the composition.
- the topical pharmaceutical composition of the present invention are in the form of a gel containing an amount of the compounds of formulas I or II for the effective topical treatment of acne and other androgen-related disorders dissolved or dispersed, preferably dissolved, in an alcohol water solvent system having an apparent pH of less than about 5.
- an alcohol water solvent system having an apparent pH of less than about 5.
- pharmaceutically acceptable adjuvants, stabilizers, preservatives and surfactants may be included.
- compositions of this invention are useful for the topical treatment ofandrogen-related conditions, e.g., acne in humans.
- the gel compositions would be applied topically twice a day, e.g., in the morning and in the evening, to the area of the skin where the acne and other androgen- related conditions lesions appear in an amount sufficient to lightly cover the entire affected area.
- the affected area of skin should be thoroughly cleansed prior to application of the pharmaceutical composition of the present invention.
- the amount of the compounds represented by formulas I and II effective to topically treat the androgen-related conditions, e.g., acne varies from a dose level of about 0.01 g/cm 2 to about 0.1g/cm 2 which may be applied as a thin film twice a day.
- Typical single doses include 0.3g/30cm 2 , 0.6g/60cm 2 1.0g/100cm 2 and 2g/200cm 2 .
- the regimen should be continued for 4 to 16 weeks or until the androgen-related conditions, e.g. the acne lesions have satisfactorily responded.
- the twice daily regimen has provided such definite beneficial results, less frequent topical application (e.g. once daily) of the pharmaceutical composition of the present invention may be used to maintain the improvement in the androgen-related conditions, e.g.the acne lesions.
- step #1 1) Add the sodium phosphate into the water (step #1) and mix until it is dissolved.
- step #4 Add the phosphoric acid into the mixing vessel (step #4) and mix for approximately 5 minutes.
- step #5 If target pH is achieved, add the drug of formula II into the mixing vessel (step #5) and mix until the drug is completely dissolved. 8) Increase the agitation speed, add the Klucel HF slowly into the mixing vessel (avoid making lumps), and mix appropriately until the batch starts to thicken and Klucel HF is completely dispersed.
- Example 1 The procedure of Example 1 was used to prepare the topical gel composition listed below.
- hydroxylcellulose used was Klucel HF available from Aqualon Company, 2711 Centervill Rd., Wilmington, DE 19850.
- the stability of the compound of formula II in ethanohwater systems [95:5(v/v)] containing phosphate buffers capable of maintaining a pH of 4.0 to 5.0 was measured at temperatures of 30°, 50° and 65°C over a twelve (12) week period.
- the stability of the compound of formula II (as measured by HPLC assay) did not significantly change in the pH range of 4 to 5 as shown in the Table 2 hereinbelow.
- the stability of the compound of formula II (1% by weight) dissolved in an ethanol: water solvent system (95:5; v/v) containing a phosphate buffer in the aqueous phase was also measured at temperatures of 30°, 50° and 65°C over a twelve (12) week period.
- the results summarized in the Table 3 herein below show that the stability of the compound of formula II is greatest at a pH of 4 (maintained by a phosphate buffer system) in an ethanol-water (97.5:2.5 v/v) solvent system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Pharmaceutical compositions for the topical treatment of androgen-related conditions, e.g., acne in humans containing an amount of the compound represented by formula (II) effective for the topical treatment of the androgen-related conditions, e.g., acne dissolved in an alcohol-water solvent system, such as ethanol-water [97.6:2.4(w/w)] and having an apparent pH in the range of about 3.5 to 4.5, and containing a gelling agent are disclosed.
Description
STABLE ANTIANDROGENIC GEL COMPOSITION
Background
This invention relates to stable pharmaceutical compositions in the form of a gel which are suitable for treating acne and other androgen-related conditions, including seborrhea, hirsutism, and androgenic alopecia, in humans and which contain an antiandrogen compound dissolved or suspended in an alcohol-water solvent system and having an apparent pH value of no more than about 5 and a gelling agent
International Publication No. WO 94/26767, published 24 November 1994 discloses antiandrogens represented by the formula I
wherein n is an integer of 2 to 3, pharmaceutical compositions containing such antiandrogens and methods of using such antiandrogens to treat androgen-dependent diseases including acne.
In the course of development of a pharmaceutical composition containing one of the antiandrogenic compounds of formula I, it was discovered that this compound is unstable and decomposes over time even at 25°C.
Thus, there is a need for a stable pharmaceutical composition containing an antiandrogen useful for topical treatment of androgen-dependent diseases including acne and having an extended shelf life suitable for commercial use.
Summary of the Invention
We have discovered that the compounds of formula I are more stable to decomposition in an alcohol-water solvent system containing less than about 5 percent by weight water than in one containing pure alcohol or an alcohol-water solvent system containing more than about 5 percent by weight water, e.g., 6.2 percent by weight water; and (2) that the presence of a glycol such as propylene glycol in an alcohol solvent system accelerates degradation of the compounds of formula I; and (3) that an apparent pH of the alcohol-water solvent system of no more than about 5, preferably in the range ofmore than about 3 to less than about 5.0 enhances the stability of the compounds of formula I.
This invention provides a pharmaceutical composition for topical treatment of androgen-related disorders which comprises (a) an amount of a compound represented by formula I effective to topically treat the androgen- related disorders
wherein n is an integer of 2 to 3; (b) an alcohol-water solvent system containing no more than about 5.0 weight percent water; and (c) a gelling agent in an amount sufficient to maintain the pharmaceutical composition in the form of a gel; and wherein the pharmaceutical composition has an apparent pH of less than or equal to about 5.
This invention further provides a pharmaceutical composition for topical treatment of androgen-related disorders which comprises:
(a) an amount of the compound represented by formula I effective to topically treat the androgen-related disorders
wherein n is an integer of 2 to 3;
(b) an ethanol-water solvent system containing no more than about 5.0 weight percent water;
(c) a buffer system capable of maintaining an apparent pH of the pharmaceutical composition at a value in the range of more than about 3 and less than about 5; and
(4) an amount of a gelling agent sufficient to maintain the pharmaceutical composition in the form of a gel.
This invention further provides a pharmaceutical composition for topical treatment of androgen-related disorders which comprises (a) an amount of the compound represented by formula II effective to topically treat the androgen- related disorders
In a more preferred embodiment of this invention, there is provided an antiandrogenic gel composition comprising an amount of the compound represented by formula II effective to topically treat androgen-related conditions
and having the name 17-α-(4-iodobutynyl)-17-β-hydroxy-4-androsten-3-one dissolved in an ethanol-water solvent system containing about 2.5 weight percent water and a buffer system capable of maintaining an apparent pH of the pharmaceutical composition at a value in the range of about 3.5 to 4.5 and an amount of a gelling agent sufficient to maintain the pharmaceutical composition in the form of a gel.
DETAILED DESCRIPTION In the course of development of the stable gel compositions of this invention, we discovered that the antiandrogens represented by formulas I and II are soluble in alcohols such as ethanol, isopropanol, oleyl alcohol, propylene glycol, octanol and 2-methyl- 1 ,4-pentandiol but are poorly soluble in water. Preformulation stability studies with the most preferred compound of formula II showed that the compound of formula II degrades rapidly at 50° C in pure ethanol, ethano water (95:5, v/v) and ethanol: propylene glycol (90:10, v/v). The compound of formula II was stable to decomposition in an alcohol-water solvent system containing no more than about 5.0 weight percent water, preferably
about 1.0 to about 4.0 weight percent of water, and more preferably about 2.0 to about 3.0 weight percent of water The alcohols found useful in the present invention include water soluble alcohols including C2 to Cs straight and branched chain alcohols. Use of ethanol or 2-propanol is preferred; use of ethanol is more preferred.
By the term " androgen-related conditions in humans" as used herein is meant those androgen-related conditions including acne, seborrhea, hirsutism, and androgenic alopecia,
The buffer systems found useful in the present invention are those buffer systems which are water soluble buffer systems, especially those soluble in the alcohol-water solvent system useful in the present invention and capable of maintaining an apparent pH of the alcohol-water solvent system of no more than about 5, preferably in the range of more than about 3 to less than about 5, more preferably a pH in the range of about 3.5 to about 4.5, and most preferably at a pH of about 4. Typically suitable buffer systems include phosphoric acid/sodium phosphate monobasic; citric acid-sodium citrate and acetic acid/sodium acetate. Use of phosphoric acid/sodium phosphate monobasic is preferred. Other buffer systems capable of maintaining an apparent pH of about 3.5 to 4.5 in an alcohol- water system containing less than 10 weight percent water may also be used.
By the term "apparent pH value" as used herein in reference to the pharmaceutical compositions of the present invention is meant that the pH value of the stable pharmaceutical composition of the present invention which comprises a water-alcohol solvent system is measured using pH electrodes
The gelling agents found useful in the present invention are those which can maintain the pharmaceutical composition of the present invention in the form of a gel. Typically suitable gelling agents include alkyl- and hydroxyalkyl ethers of cellulose including hydroxyethylcellulose, hydroxypropylcellulose, methylcellulose derivatives as well as carboxypolymethylene (which is highly ionic and slightly acidic) such as those carboxyvinylpolymers sold under the tradenames carbomers and carbopol. Use of hydroxypropylcellulose is preferred. The amount of gelling agent found effective to maintain the pharmaceutical compositions of this invention in the form of a gel is at least about 2 weight percent of the composition, preferably in the range of about 2 to about 5 weight percent , and more preferably about 2 to about 3 weight percent , and most preferably about 2.5 weight percent of the composition.
The topical pharmaceutical composition of the present invention are in the form of a gel containing an amount of the compounds of formulas I or II for the
effective topical treatment of acne and other androgen-related disorders dissolved or dispersed, preferably dissolved, in an alcohol water solvent system having an apparent pH of less than about 5. In addition to the active ingredient, the alcohol-water solvent, the gelling agent and buffer system, pharmaceutically acceptable adjuvants, stabilizers, preservatives and surfactants may be included.
The pharmaceutical compositions of this invention are useful for the topical treatment ofandrogen-related conditions, e.g., acne in humans. Typically the gel compositions would be applied topically twice a day, e.g., in the morning and in the evening, to the area of the skin where the acne and other androgen- related conditions lesions appear in an amount sufficient to lightly cover the entire affected area. The affected area of skin should be thoroughly cleansed prior to application of the pharmaceutical composition of the present invention. The amount of the compounds represented by formulas I and II effective to topically treat the androgen-related conditions, e.g., acne varies from a dose level of about 0.01 g/cm2 to about 0.1g/cm2 which may be applied as a thin film twice a day. Typical single doses include 0.3g/30cm2, 0.6g/60cm2 1.0g/100cm2 and 2g/200cm2. The regimen should be continued for 4 to 16 weeks or until the androgen-related conditions, e.g. the acne lesions have satisfactorily responded. Once the twice daily regimen has provided such definite beneficial results, less frequent topical application (e.g. once daily) of the pharmaceutical composition of the present invention may be used to maintain the improvement in the androgen-related conditions, e.g.the acne lesions.
PHARMACEUTICAL COMPOSITIONS
The following examples illustrate the formulation and method of manufacture and packaging of compositions of the present invention. It will be apparent to those skilled in the art that many modifications thereof may be practical without departing from the purpose and intent of this invention.
EXAMPLE 1 The topical gel pharmaceutical compositions of this invention contain the following ingredient present in the listed amounts.
Ingredient Amount
( g/g)
Compound of formula II 1 8.00-12.00 hydroxypropylcellulose NF2 20.00-30.00 sodium phosphate monobasic, USP 0.025-0.035 phosphoric acid, NF 1.60-2.40 water, purified(USP) 19.0-29.0 ethanol, USP 929-951
1. The compound of formula II was prepared in accordance with the procedures of Example 2 and Scheme 2 of WO 94/26767, published 24 Nov. 1994.
2. Available under the tradename Klucel™NF from Aqualon Company, 2711 Centervill Rd., Wilmington, DE 19850.
The following procedure was used to prepare the composition:
1 ) Charge the water into an appropriate stainless steel container equipped with a suitable mixer.
2) Add the sodium phosphate into the water (step #1) and mix until it is dissolved.
3) Charge the alcohol into a large stainless steel vessel equipped with a suitable mixer.
4) Transfer aqueous solution (step #2) into the alcohol vessel (step #3) and start mixing.
5) Add the phosphoric acid into the mixing vessel (step #4) and mix for approximately 5 minutes.
6) Measure the pH of the alcohol/buffer solution (target pH=4.0 ± 0.2). If the target pH is not achieved discard the material (alcohol/buffer solution).
7) If target pH is achieved, add the drug of formula II into the mixing vessel (step #5) and mix until the drug is completely dissolved.
8) Increase the agitation speed, add the Klucel HF slowly into the mixing vessel (avoid making lumps), and mix appropriately until the batch starts to thicken and Klucel HF is completely dispersed.
9) Decrease the agitation speed appropriately and continue mixing for approximately 15 minutes. Stop agitation and leave overnight.
10) Fill into the specified epoxy-lined aluminum tubes.
11) Store at 2° to 25° C.
EXAMPLE 2
The procedure of Example 1 was used to prepare the topical gel composition listed below.
1. The compound of formula II was prepared in accordance with the procedures of Example 2 and Scheme 2 of WO 94/26767, published Nov. 24, 1994..
2. The hydroxylcellulose used was Klucel HF available from Aqualon Company, 2711 Centervill Rd., Wilmington, DE 19850.
The most preferred gel pharmaceutical composition of the present invention prepared in accordance with the procedure of Example 2 was stable to decomposition of the compound of formula II when it was stored at a temperature of 25°C for 24 months. The stability results are summarized in Table 1 hereinbelow.
Table 1
Stability of the Composition of Example 2 at 25°C and 60% Relative Humidity
Time Assay''
(months) % Compound of formula II as labeled strength
0 103 3 102 6 102 9 101 12 100 18 104 24 98
1 HPLC analysis.
2 5% overcharge of II was added to the batch.
The stability of the compound of formula II in ethanohwater systems [95:5(v/v)] containing phosphate buffers capable of maintaining a pH of 4.0 to 5.0 was measured at temperatures of 30°, 50° and 65°C over a twelve (12) week period. The stability of the compound of formula II (as measured by HPLC assay) did not significantly change in the pH range of 4 to 5 as shown in the Table 2 hereinbelow.
Table 2
Stability of the Compound of Formula II1 in ethanol: water2 Containing Phosphate Buffers at Various pH Values and Temperatures.
(1) Analysis of the compound of formula I by HPLC with an external standard.
(2) The ethanol:water is 95:5,v/v, equivalent to 93.8:6.2, w/w.
The stability of the compound of formula II (1% by weight) dissolved in an ethanol: water solvent system (95:5; v/v) containing a phosphate buffer in the aqueous phase was also measured at temperatures of 30°, 50° and 65°C over a twelve (12) week period. The results summarized in the Table 3 herein below show that the stability of the compound of formula II is greatest at a pH of 4 (maintained by a phosphate buffer system) in an ethanol-water (97.5:2.5 v/v) solvent system
Table 3
Stability of the Compound of Formula II1 in Various Ethanol: Water Solvent Systems containing a Phosphate Buffer at pH=4and at Temperatures of 30°, 50° and 65°C.
(1) HPLC analysis
(2) 96.9:3.1 , w/w
(3) 93.8:6.2,w/w
(4) 90.7:9.3,w/w
Claims
1. A pharmaceutical composition for topical treatment of androgen- related disorders which comprises (a) an amount of a compound represented by formula I effective to topically treat the androgen-related disorders
wherein n is an integer of 1 to 3; (b) an alcohol-water solvent system containing no more than about 5.0 weight percent water; and (c) a gelling agent in an amount sufficient to maintain the pharmaceutical composition in the form of a gel; and wherein the pharmaceutical composition has an apparent pH of less than or equal to about 5.
2. The pharmaceutical composition of claim 1 wherein the alcohol is ethanol.
3. The pharmaceutical composition of claim 1 wherein the pH is maintained in the range of more than about 3 and less than about 5.
4. The pharmaceutical composition of claim 1 wherein n in formula I is
5. A pharmaceutical composition for topical treatment of androgen- related disorders which comprises:
(a) an amount of the compound represented by formula I effective to topically treat the androgen-related disorders. 
wherein n is an integer of 2 to 3;
(b) an ethanol-water solvent system containing no more than about 5.0 weight percent water;
(c) a buffer system capable of maintaining an apparent pH of the pharmaceutical composition at a value in the range of more than 3 to less than about 5; and
(4) an amount of a gelling agent sufficient to maintain the pharmaceutical composition in the form of a gel.
The pharmaceutical composition of claim 5 wherein n in formula is 2.
7. The pharmaceutical composition of claim 5 wherein the ethanol- water solvent system contains about 1.0 to about 4.0 weight percent water.
8. The pharmaceutical composition of claim 5 wherein the apparent pH is in the range of about 3.5 to about 4.5.
9. A pharmaceutical composition for topical treatment of androgen- related disorders which comprises (a) an amount of the compound of formula II effective for the topical treatment of the androgen-related disorders; 
(b) an ethanol-water solvent system containing more than about 1.0 to about 4.0 percent by weight water; (c) a buffer system capable of maintaining an apparent pH of the pharmaceutical composition in the range of about 3.5 to 4.5 and (d) an amount of a gelling agent sufficient to maintain the pharmaceutical composition in the form of a gel.
10. The pharmaceutical composition of claim 9 wherein the gelling agent is a hydroxypropylcellulose.
11. The pharmaceutical composition of claim 9 comprising the ingredients present in the following amounts.
Ingredient Amount
(mg/g)
Compound of formula II 8.00-12.00 hydroxypropylcellulose 20.00-30.00 sodium phosphate monobasic 0.025-0.035 phosphoric acid 1.60-2.40 water 19.0-29.0 ethanol 929-951
12. The pharmaceutical composition of claim 9 comprising the ingredients present in the following amounts.
Ingredient Amount
(mg/g)
Compound of formula II 10.00 hydroxypropylcellulose 25.00 Ingredient Amount sodium phosphate monobasic 0.03 phosphoric acid 2.00 water 24.07
Ethanol 938.90
13. The pharmaceutical composition of claim 9 wherein the ethanol- water solvent system contains about 2.0 to about 3.0 weight percent water
14. The pharmaceutical composition of claim 9 wherein the androgen- related condition is acne.
15. The pharmaceutical composition of claim 9 wherein the androgen- related condition is seborrhea
16 The pharmaceutical composition of claim 9 wherein the androgen- related condition is hirsutism
17. A method of treating acne which comprises administering to a human in need of such treating an amount of the pharmaceutical composition of claim 1 sufficient for effectively topically treating acne.
18 A method of treating seborrhea which comprises administering to a human in need of such treating an amount of the pharmaceutical composition of claim 1 sufficient for effectively topically treating seborrhea.
19. A method of treating hirsutism which comprises administering to a human in need of such treating an amount of the pharmaceutical composition of claim 1 sufficient for effectively topically treating hirsutism.
20 A method of treating androgenic alopecia which comprises administering to a human in need of such treating an amount of the pharmaceutical composition of claim 1 sufficient for effectively topically treating androgenic alopecia.
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002309123A CA2309123A1 (en) | 1997-11-07 | 1998-11-05 | Stable antiandrogenic gel composition |
| JP2000520134A JP2001522805A (en) | 1997-11-07 | 1998-11-05 | Anti-androgen gel composition |
| EP98956445A EP1028731A2 (en) | 1997-11-07 | 1998-11-05 | Stable antiandrogenic gel composition |
| AU12969/99A AU1296999A (en) | 1997-11-07 | 1998-11-05 | Stable antiandrogenic gel composition |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/966,263 US5879711A (en) | 1997-11-07 | 1997-11-07 | Stable antiandrogenic gel composition |
| US08/966,263 | 1997-11-07 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO1999024042A2 true WO1999024042A2 (en) | 1999-05-20 |
| WO1999024042A3 WO1999024042A3 (en) | 1999-07-22 |
Family
ID=25511128
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1998/023226 Ceased WO1999024042A2 (en) | 1997-11-07 | 1998-11-05 | Stable antiandrogenic gel composition |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US5879711A (en) |
| EP (1) | EP1028731A2 (en) |
| JP (1) | JP2001522805A (en) |
| AU (1) | AU1296999A (en) |
| CA (1) | CA2309123A1 (en) |
| WO (1) | WO1999024042A2 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2282185A1 (en) | 1999-09-10 | 2001-03-10 | Warren Steck | Oenothein medicaments |
| CA2542755A1 (en) * | 2003-10-17 | 2005-04-28 | Medrx Co., Ltd. | Biguanide drug-containing jelly preparation |
| JP5840107B2 (en) * | 2012-06-17 | 2016-01-06 | コスメディ製薬株式会社 | Hyaluronic acid gel and method for producing the same |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3290293A (en) * | 1961-12-01 | 1966-12-06 | Merck & Co Inc | 4-androsteno-[3, 2-c] pyrazoles |
| BE642575A (en) * | 1963-01-16 | |||
| US3341527A (en) * | 1965-02-16 | 1967-09-12 | Syntex Corp | 17beta-tetrahydrofuranyloxy androstanes |
| DE1526287A1 (en) * | 1966-09-15 | 1970-04-02 | Daimler Benz Ag | Method for injecting a controllable fuel quantity into the compression stroke of an externally ignited internal combustion engine and internal combustion engine for carrying out the method |
| AU1005270A (en) * | 1969-01-16 | 1971-07-08 | F. Hoffmann-Laroche & Co. Aktiengesellschaft | 19 homo steroids |
| US4380549A (en) * | 1975-07-23 | 1983-04-19 | Scott Eugene J Van | Topical treatment of dry skin |
| US4220775A (en) * | 1979-03-15 | 1980-09-02 | Merck & Co., Inc. | Preparation of 4-aza-17-substituted-5α-androstan-3-ones useful as 5α-reductase inhibitors |
| DE3434448A1 (en) * | 1984-09-17 | 1986-03-27 | Schering AG, 1000 Berlin und 4709 Bergkamen | METHOD FOR PRODUCING PREGNAN DERIVATIVES |
| US4775529A (en) * | 1987-05-21 | 1988-10-04 | Schering Corporation | Steroid lotion |
| US5116615A (en) * | 1989-01-27 | 1992-05-26 | Immunolytics, Inc. | Method for treating benign prostatic hypertrophy |
| ZA901847B (en) * | 1989-03-10 | 1991-10-30 | Endorecherche Inc | Combination therapy for the treatment of estrogen sensitive diseases |
| AU5856090A (en) * | 1989-07-07 | 1991-02-06 | Endorecherche Inc. | Androgen derivatives for use in the inhibition of sex steroid activity |
| DE4021433A1 (en) * | 1990-07-04 | 1992-01-09 | Schering Ag | ANTIANDROGEN WITH STEROID (3,2-C) PYRAZOLE STRUCTURE |
| US5723149A (en) * | 1990-11-21 | 1998-03-03 | Lvmh Recherche | Use of medicago saponins for the preparation of cosmetic or pharmaceutical compositions, especially dermatological compositions, promoting renewal of the epidermis, stimulating hair regrowth or delaying hair loss |
| DK0567271T3 (en) * | 1992-04-20 | 1998-02-16 | Sankyo Co | Steroid derivatives for the treatment of prostate hypertrophy, method of preparation thereof and applications thereof |
| UA35589C2 (en) * | 1992-05-21 | 2001-04-16 | Андорешерш Інк. | INHIBITORS OF TESTOSTERONE 5-<font face="Symbol">a</font>-REDUCTASE activity, pharmaceutical composition and a method for inhibiting activity of testosterone 5-<font face="Symbol">a</font>-REDUCTASE |
| US5605929A (en) * | 1992-05-27 | 1997-02-25 | Arch Development Corp. | Methods and compositions for inhibiting 5α-reductase activity |
| ATE197458T1 (en) * | 1993-05-17 | 2000-11-11 | Endorech Inc | IMPROVED ANTIANDROGENS |
| FR2712495B1 (en) * | 1993-11-16 | 1996-01-05 | Roussel Uclaf | Application of Óoenotheine B to obtain a medicament intended for the treatment of disorders linked to hyperandrogenism, and the pharmaceutical compositions containing it. |
-
1997
- 1997-11-07 US US08/966,263 patent/US5879711A/en not_active Expired - Lifetime
-
1998
- 1998-11-05 EP EP98956445A patent/EP1028731A2/en not_active Withdrawn
- 1998-11-05 CA CA002309123A patent/CA2309123A1/en not_active Abandoned
- 1998-11-05 AU AU12969/99A patent/AU1296999A/en not_active Abandoned
- 1998-11-05 JP JP2000520134A patent/JP2001522805A/en not_active Withdrawn
- 1998-11-05 WO PCT/US1998/023226 patent/WO1999024042A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CA2309123A1 (en) | 1999-05-20 |
| EP1028731A2 (en) | 2000-08-23 |
| WO1999024042A3 (en) | 1999-07-22 |
| JP2001522805A (en) | 2001-11-20 |
| US5879711A (en) | 1999-03-09 |
| AU1296999A (en) | 1999-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5696105A (en) | Antifungal nail composition | |
| CA2373821C (en) | Topical compositions for prostaglandin e1 delivery | |
| EP0101178B1 (en) | Topical anti-inflammatory compositions | |
| US5219877A (en) | Lauryl alcohol as skin penetration enhancer for topical imidazole agents | |
| EP0221176B1 (en) | Pharmaceutical vehicles for recucing transdermal flux | |
| US4829088A (en) | Medicament for the treatment of inflammations of the eye | |
| EP0362270B2 (en) | Steroid lotion | |
| EP0471872A1 (en) | Antifungal gel formulations | |
| US20120165302A1 (en) | Antifungal formulations | |
| GB2058563A (en) | Topical triethylenetetramine pharmaceutical compositions | |
| JPS646173B2 (en) | ||
| EP0055029A2 (en) | Preparations for the treatment of dermatoses | |
| US5208015A (en) | Topical anti-fungal agents having anti-inflammatory activity | |
| US5879711A (en) | Stable antiandrogenic gel composition | |
| JPH07557B2 (en) | Composition for treating dermatitis | |
| US5036050A (en) | Compositions containing thymopentin for topical treatment of skin disorders | |
| EP1309352A1 (en) | Antifungal ketoconazole composition for topical use | |
| MXPA00004434A (en) | Stable antiandrogenic gel composition | |
| GB2131693A (en) | Composition for local corticotherapy containing hydrocortisone | |
| KR930000050B1 (en) | Antibacterial Gel Blend | |
| JPH10182458A (en) | Topical composition containing indomethacin | |
| CA1319105C (en) | Antifungal gel formulations | |
| JPH04108722A (en) | hair growth agent | |
| JPH05117141A (en) | Antiinflammatory analgesic gel preparation containing adrenal essence | |
| JPH0437048B2 (en) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CZ EE GD GE HR HU ID IL IS JP KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK SL TJ TM TR TT UA UZ VN YU |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CZ EE GD GE HR HU ID IL IS JP KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK SL TJ TM TR TT UA UZ VN YU |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 520134 Kind code of ref document: A Format of ref document f/p: F |
|
| ENP | Entry into the national phase |
Ref document number: 2309123 Country of ref document: CA Ref country code: CA Ref document number: 2309123 Kind code of ref document: A Format of ref document f/p: F |
|
| NENP | Non-entry into the national phase |
Ref country code: KR |
|
| WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2000/004434 Country of ref document: MX |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1998956445 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 1998956445 Country of ref document: EP |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 1998956445 Country of ref document: EP |